MaxCyte’s high performance cell engineering technology delivered CRISPR-Cas9 with high efficiency & CHO-S cell viability enabling rapid generation of an MGAT1-deficient CHO cell line via precision #CRISPR gene disruption. Our app note provides the details: http://ow.ly/j9rQ50JjvOS

MaxCyte is happy to sponsor SETGyC in Sevilla, Spain May 30 – June 1, 2022. See you there! http://ow.ly/UuH250JiWsk

Autologous cell therapies are a new frontier, but they face concerns over costs and safety. Don’t miss our @Labroots webinar TODAY as we discuss how researchers are combating these hurdles, including using our ExPERT technology as a non-viral alternative. http://ow.ly/fAEQ50JgvSb

Our @Labroots webinar is tomorrow! Learn about the groundbreaking work researchers are doing to combat the hurdles of autologous cell therapies, including using our ExPERT technology as a non-viral alternative. There’s still time to register: http://ow.ly/7FOl50Jfrzm

#ISCT2022 was a huge success! If you missed our events, we’ve got you covered. Check out our presentation and related poster to learn how UCSF achieved scalable electroporation of adult keratinocytes with multiplexed CRISPR using MaxCyte's ExPERT platform. http://ow.ly/U1uw50Je4EJ

Load More...
MaxCyte’s high performance cell engineering technology delivered CRISPR-Cas9 with high efficiency & CHO-S cell viability enabling rapid generation of an MGAT1-deficient CHO cell line via precision #CRISPR gene disruption. Our app note provides the details: https://t.co/VT2mNdJYiQ https://t.co/evsnNrzoIt MaxCyte_info photo
MaxCyte is happy to sponsor SETGyC in Sevilla, Spain May 30 – June 1, 2022. See you there! https://t.co/onYBqZFdRK https://t.co/clF3OZOdrf MaxCyte_info photo
Autologous cell therapies are a new frontier, but they face concerns over costs and safety. Don’t miss our @Labroots webinar TODAY as we discuss how researchers are combating these hurdles, including using our ExPERT technology as a non-viral alternative. https://t.co/0JRJFc1vl3 https://t.co/4YDWN5B0Mw MaxCyte_info photo
Our @Labroots webinar is tomorrow! Learn about the groundbreaking work researchers are doing to combat the hurdles of autologous cell therapies, including using our ExPERT technology as a non-viral alternative. There’s still time to register: https://t.co/6Hl4X3xnBc https://t.co/gGSPeDJVgz MaxCyte_info photo